BNF for Children 2022-2023


85,74 81,45

Autor: Paediatric Formulary Committee
Editor: Pharmaceutical Press
Edición: 1
Páginas: 1264
Año edición: SEPTIEMBRE 2022
SKU: 9780857114297 Categories ,

Published jointly by the British Medical Association, Royal Pharmaceutical Society, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group

The BNF for Children is the first choice for concise medicines information for children. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.

The new edition provides up-to-date guidance on prescribing, dispensing, and administering medicines to children, plus legal and professional guidelines.

Recommendations in the BNF for Children have been constructed on the basis of authoritative sources, emerging evidence, best practice guidelines and advice from a network of paediatric experts. The process is overseen by a paediatric formulary committee.

Extensive content updates in the BNF for Children 2022-2023 edition include:

New monographs for:

  • Acarizax® [house dust mite extract] for house dust mite allergic rhinitis
  • Adakveo® [crizanlizumab] for vaso-occlusive crises in sickle-cell disease
  • Cibinqo® [abrocitinib] for atopic eczema
  • Dificlir® [fidaxomicin] for Clostridioides difficile infection
  • Evrysdi® [risdiplam] for 5q spinal muscular atrophy
  • Fintepla® [fenfluramine] for adjunctive therapy of seizures associated with Dravet syndrome
  • Givlaari® [givosiran] for acute hepatic porphyria
  • Keytruda® [pembrolizumab] for classical Hodgkin lymphoma
  • Koselugo® [selumetinib] for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1
  • Liraglutide for weight management or type 2 diabetes mellitus
  • Orladeyo® [berotralstat] for hereditary angioedema
  • Pradaxa® [dabigatran etexilate] for prophylaxis or treatment of venous thromboembolism
  • Rinvoq® [upadacitinib] for atopic eczema
  • Ruconest® [conestat alfa] for hereditary angioedema in patients with C1-esterase inhibitor deficiency
  • Ryaltris® [mometasone furoate with olopatadine] for allergic rhinitis
  • Taltz® [ixekizumab] for plaque psoriasis
  • Ultomiris® [ravulizumab] for atypical haemolytic uraemic syndrome or paroxysmal nocturnal haemoglobinuria
  • Xarelto® [rivaroxaban] for prophylaxis or treatment of venous thromboembolism
  • Xeljanz® [tofacitinib] for polyarticular juvenile idiopathic arthritis or juvenile psoriatic arthritis
  • Xevudy® [sotrovimab] for COVID-19
  • Xofluza® [baloxavir marboxil] for post-exposure prophylaxis or treatment of influenza
  • BNF for Children 2022-2023 is an essential publication, it provides you with:
    • Up-to-date information on prescribing, dispensing, and administering medicines
    • Authoritative, independent guidance on best practice enabling you to select safe and effective medicines
    • Information you know you can trust for quality, reliability, and independence
    • Everything you need at your fingertips, all in one book


No hay valoraciones aún.

Sé el primero en valorar “BNF for Children 2022-2023”

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

Ir arriba